Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Abstract Immune-checkpoint inhibitors (ICIs) have transformed patient care in oncology but are associated with a unique spectrum of organ-specific inflammatory toxicities known as immune-related adverse events (irAEs)
Past performance does not guarantee future results
its a collaboration built on trust, precision, and shared goals
doi: 10.1016/j.jep.2024.119224, 14
The bioavailability problem: what happens to oral GLP-1 agonists in the digestive system Bioavailability measures the percentage of an administered dose that reaches systemic circulation unchanged
Krug SM, Amasheh M, Dittmann I, Christoffel I, Fromm M, Amasheh S
US$ 22.30
US$ 21.06
US$ 28.15
US$ 25.73
US$ 24.60
